Lobbying

Nephron Pharmaceuticals's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q4 2022; the issues it reports most are Pharmacy and Health Issues.

Nephron Pharmaceuticals

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$150K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Nephron Pharmaceuticals lobbying by quarter
Nephron Pharmaceuticals lobbying by quarter
QuarterAmountReports
Q4 2022$45K1
Q1 2023$01
Q2 2023$01
Q3 2023$00
Q4 2023$00
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$01
Q2 2025$45K1
Q3 2025$45K1
Q4 2025$50K1
Q1 2026$50K1
Q2 2026$50K1
Q3 2026$00

By issue

  • Pharmacy$240K · 5 reports
  • Health issues$22.5K · 1 reports
  • Manufacturing$22.5K · 1 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Health & Human Services, Dept of (HHS)6 reports
  • Commerce, Dept of (DOC)1 reports
  • Defense, Dept of (DOD)1 reports
  • Executive Office of the President (EOP)1 reports
  • Food & Drug Administration (FDA)1 reports
  • HOUSE OF REPRESENTATIVES1 reports
  • Intl Trade Administration (ITA)1 reports
  • SENATE1 reports
  • White House Office1 reports

Firms it paid

Firm
The Vogel Group$285K9 quarters

Former officials lobbying for it

Former position
ALEXANDER NICHOLAS VOGEL srFormer Chief Counsel, Senate Majority Leader Bill FristQ2 2026

Lobbying reports

Filed by
07/19for Q2The Vogel Group$50K
04/20for Q1The Vogel Group$50K
01/19for Q4 2025The Vogel Group$50K
25/10/19for Q3 2025The Vogel Group$45K
25/07/20for Q2 2025The Vogel Group$45K
25/04/20for Q1 2025The Vogel GroupUnder $5,000
25/04/07for Q2 2025The Vogel GroupUnder $5,000
23/07/19for Q2 2023The Vogel GroupUnder $5,000
23/04/17for Q1 2023The Vogel GroupUnder $5,000
23/01/20for Q4 2022The Vogel Group$45K